• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma

by | Sep 12, 2024 | Uncategorized

Source: CureToday articles A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with newly diagnosed, transplant-eligible multiple myeloma. Read More

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

by | Sep 6, 2024 | Uncategorized

Source: CureToday articles Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. Read More

Moving Forward in Multiple Myeloma: Earlier Lines of CAR-T Cell Therapy

by | Sep 4, 2024 | Uncategorized

Source: CureToday articles Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines. Read More

Speeding Up With CAR-T Cell Therapy in Multiple Myeloma

by | Sep 3, 2024 | Uncategorized

Source: CureToday articles CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Read More

Multiple Myeloma Remission: A Glimmer of Hope

by | Aug 30, 2024 | Uncategorized

Source: CureToday articles As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. Read More

10 Multiple Myeloma Questions and Answers: Treatments and Side Effects

by | Aug 29, 2024 | Uncategorized

Source: CureToday articles Patients with multiple myeloma now have several available treatment options, so it’s important to have answers to some of the frequently asked questions. Read More
« Older Entries
Next Entries »

Recent Content

  • Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
  • Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma
  • Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
  • High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
  • CAR-T cell therapy in Multiple Myeloma: current status and future challenges
  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT